Retrospective Cohort Study
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Dec 21, 2023; 29(47): 6111-6121
Published online Dec 21, 2023. doi: 10.3748/wjg.v29.i47.6111
Comparison of fecal calprotectin levels and endoscopic scores for predicting relapse in patients with ulcerative colitis in remission
Natsuki Ishida, Tatsuhiro Ito, Kenichi Takahashi, Yusuke Asai, Takahiro Miyazu, Tomohiro Higuchi, Satoshi Tamura, Shinya Tani, Mihoko Yamade, Moriya Iwaizumi, Yasushi Hamaya, Satoshi Osawa, Ken Sugimoto
Natsuki Ishida, Tomohiro Higuchi, Satoshi Osawa, Department of Endoscopic and Photodynamic Medicine, Hamamatsu University of School of Medicine, Hamamatsu 431-3192, Japan
Tatsuhiro Ito, Kenichi Takahashi, Yusuke Asai, Takahiro Miyazu, Satoshi Tamura, Shinya Tani, Mihoko Yamade, Yasushi Hamaya, Ken Sugimoto, First Department of Medicine, Hamamatsu University of School of Medicine, Hamamatsu 431-3192, Japan
Moriya Iwaizumi, Department of Laboratory Medicine, Hamamatsu University of School of Medicine, Hamamatsu 431-3192, Japan
Author contributions: Ishida N made the concept of this study; Ishida N and Sugimoto K designed the study; Ishida N, Ito T, Takahashi K, Asai Y, Miyazu T, Higuchi T, Tamura S and Tani S collected the data; Yamade M, Iwaizumi M, and Hamaya Y analyzed the data; Ishida N and Sugimoto K wrote the article; and Hamaya Y and Osawa S provided critical insights regarding article preparation.
Institutional review board statement: The study was reviewed and approved for publication by our Institutional Reviewer.
Informed consent statement: Informed consent from patients was obtained in the form of an opt-out form on the hospital website.
Conflict-of-interest statement: The authors have no conflicts of interest related to the manuscript.
Data sharing statement: No additional data are available.
STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ken Sugimoto, MD, PhD, Professor, First Department of Medicine, Hamamatsu University of School of Medicine, No. 1-20-1 Handayama, Hamamatsu 431-3192, Japan. sugimken@hama-med.ac.jp
Received: June 10, 2023
Peer-review started: June 10, 2023
First decision: August 8, 2023
Revised: August 24, 2023
Accepted: November 29, 2023
Article in press: November 29, 2023
Published online: December 21, 2023
Core Tip

Core Tip: We evaluated the usefulness of fecal calprotectin and endoscopic scores, including the Mayo Endoscopic Subscore, Ulcerative Colitis Endoscopic Index of Severity (UCEIS), and Ulcerative Colitis Colonoscopic Index of Severity, in patients with ulcerative colitis (UC) in remission. All three endoscopic scores and fecal calprotectin are useful for predicting relapse in UC. The UCEIS is easy to evaluate and appears to be highly accurate in predicting relapse.